Valuation : Precision BioSciences, Inc.

Market Cap 232M 199M 186M 171M 321M 22.14B 322M 2.21B 863M 11.16B 870M 852M 36.94B P/E 2026 *
-2.32x
P/E 2027 * -3.1x
Enterprise Value 232M 199M 186M 171M 321M 22.14B 322M 2.21B 863M 11.16B 870M 852M 36.94B EV / Sales 2026 *
17.2x
EV / Sales 2027 * 26.1x
Free-Float
91.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Precision BioSciences, Inc.

1 day-1.06%
1 week-3.67%
Current month+20.17%
1 month+15.86%
3 months+10.67%
6 months+100.00%
Current year+101.92%
1 week 8.21
Extreme 8.21
8.82
1 month 6.7
Extreme 6.7
9.34
Current year 3.53
Extreme 3.53
9.62
1 year 3.53
Extreme 3.53
9.62
3 years 3.53
Extreme 3.53
19.43
5 years 3.53
Extreme 3.53
431.4
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Executive Officer 48 15/10/2021
Chief Tech/Sci/R&D Officer 53 26/01/2006
Director of Finance/CFO 45 01/08/2026
Director TitleAgeSince
Chairman 68 01/11/2020
Director/Board Member 65 10/03/2020
Director/Board Member 67 12/04/2021
Date Insider Type Main position Quantity % Market Cap.
8/1/26 A Other

Chief Financial Officer

251,581 1.0451%
8/1/26 A Other

Controller/Auditor

48,872 0.2030%
8/1/26 A Other

Chief Technology Officer

236,188 0.9812%
Change 5-day change 1-year change 3-year change Capi.($)
-1.06%-3.67%+67.66%-45.10% 232M
-0.31%-0.95%+2.98%+23.36% 51.14B
+2.65%+4.45%+481.36%+567.32% 47.4B
+0.33%+2.47%+38.97%+19.80% 43.19B
-0.88%+0.90%+24.11%+87.74% 42.35B
-2.27%-3.02%+14.22%+51.50% 33.23B
-1.21%-0.17%+29.16%+135.38% 17.07B
-0.36%-2.14% - - 16.38B
-0.36%-0.14%+12.18%+28.43% 14.76B
+0.44%+1.70%+82.07%+47.92% 14.15B
Average -0.30%+0.20%+83.64%+101.82% 27.99B
Weighted average by Cap. -0.05%+1.04%+106.25%+143.31%

Financials

2026 *2027 *
Net sales 13.48M 11.58M 10.84M 9.92M 18.69M 1.29B 18.75M 128M 50.16M 649M 50.63M 49.53M 2.15B 8.88M 7.62M 7.13M 6.53M 12.3M 848M 12.34M 84.46M 33.02M 427M 33.32M 32.6M 1.41B
Net income -94.18M -80.84M -75.69M -69.31M -131M -9B -131M -896M -350M -4.53B -354M -346M -15B -96.95M -83.22M -77.91M -71.34M -134M -9.26B -135M -923M -361M -4.67B -364M -356M -15.44B
Net Debt - -
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Employees
67
Date Price Change Volume
27/08/26 $8.400 -1.06% 275,051
26/08/26 $8.490 -0.70% 263,208
25/08/26 $8.550 +1.18% 418,190
24/08/26 $8.450 -4.52% 232,783
21/08/26 $8.850 +1.49% 305,180
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.400USD
Average target price
29.40USD
Spread / Average Target
+250.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DTIL Stock